Combination product of dermal matrix, human mesenchymal stem cells, and timolol promotes diabetic wound healing in mice

Volume: 9, Issue: 11, Pages: 1353 - 1364
Published: Jul 28, 2020
Abstract
Diabetic foot ulcers are a major health care concern with limited effective therapies. Mesenchymal stem cell (MSC)-based therapies are promising treatment options due to their beneficial effects of immunomodulation, angiogenesis, and other paracrine effects. We investigated whether a bioengineered scaffold device containing hypoxia-preconditioned, allogeneic human MSCs combined with the beta-adrenergic antagonist timolol could improve impaired...
Paper Details
Title
Combination product of dermal matrix, human mesenchymal stem cells, and timolol promotes diabetic wound healing in mice
Published Date
Jul 28, 2020
Volume
9
Issue
11
Pages
1353 - 1364
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.